J
Jedd D. Wolchok
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 795
Citations - 154490
Jedd D. Wolchok is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ipilimumab & Immune system. The author has an hindex of 140, co-authored 713 publications receiving 123336 citations. Previous affiliations of Jedd D. Wolchok include Ludwig Institute for Cancer Research & University of York.
Papers
More filters
Journal ArticleDOI
Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
TL;DR: The per-patient cost of advanced melanoma is high, however, when combining estimated monthly costs with median follow-up duration, total costs incurred by Medicare appear to be highest for patients diagnosed at stage IIIA/B.
Journal ArticleDOI
Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials.
Céleste Lebbé,Jeffrey S. Weber,Michele Maio,Bart Neyns,Kaan Harmankaya,Omid Hamid,Steven J. O'Day,Kevin M. Chin,Diane Opatt McDowell,L. Cykowski,Brent McHenry,Jedd D. Wolchok +11 more
TL;DR: The present analyses provide survival follow-up of >5 years in four phase II trials of Ipi in MM, which shows improved overall survival in patients with metastatic melanoma.
Journal ArticleDOI
Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors.
Margaret K. Callahan,Kunle Odunsi,Mario Sznol,John Nemunaitis,Patrick A. Ott,Patrick M. Dillon,Andrew J. Park,Paul Schwarzenberger,Toni Ricciardi,Mary J. Macri,Aileen Ryan,Ralph Venhaus,Jedd D. Wolchok +12 more
TL;DR: DUR is a human IgG1 monoclonal antibody that blocks PD-L1 that blocks CTLA-4 and TRE is ahuman IgG2 mAb inhibitor of CTla-4 that blocking these checkpoints can result in antitumor activity in some patients.
Journal ArticleDOI
Checkpoint modulation in melanoma: an update on ipilimumab and future directions.
TL;DR: Ipilimumab, an anti-cytotoxic T-lymphocyte antigen 4 antibody, was the first therapy demonstrated to improve overall survival in melanoma and paved the way for rapid development of second-generation immunomodulatory antibodies such as inhibitors of the programmed cell death 1 receptor axis.
Journal ArticleDOI
Is Tumor Immunity the Same Thing As Autoimmunity? Implications for Cancer Immunotherapy
TL;DR: Direct delivery of the B7 costimulatory molecule encoded by a vaccinia virus into melanoma lesions induced objective clinical responses in two patients and was associated with vitiligo in three patients, indicating a direct association between antitumor immunity and autoimmunity.